Pieris Pharmaceuticals Inc (NASDAQ:PIRS) – Research analysts at William Blair issued their FY2017 earnings estimates for Pieris Pharmaceuticals in a research note issued on Wednesday. William Blair analyst M. Phipps forecasts that the biotechnology company will earn ($0.44) per share for the year. William Blair currently has a “Outperform” rating on the stock. William Blair also issued estimates for Pieris Pharmaceuticals’ Q4 2017 earnings at $0.14 EPS, FY2018 earnings at ($0.70) EPS, FY2019 earnings at ($0.86) EPS, FY2020 earnings at ($1.01) EPS, FY2021 earnings at ($1.77) EPS and FY2022 earnings at ($1.84) EPS.
A number of other brokerages have also recently issued reports on PIRS. HC Wainwright increased their price objective on Pieris Pharmaceuticals from $9.00 to $12.00 and gave the stock a “buy” rating in a report on Tuesday, January 16th. BidaskClub raised Pieris Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Wednesday, December 27th. Finally, ValuEngine cut Pieris Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, December 1st. One analyst has rated the stock with a sell rating and five have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $10.00.
Pieris Pharmaceuticals (NASDAQ:PIRS) last issued its quarterly earnings data on Wednesday, November 8th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.05. The business had revenue of $3.93 million for the quarter, compared to analysts’ expectations of $1.52 million. Pieris Pharmaceuticals had a negative return on equity of 221.93% and a negative net margin of 321.83%. The company’s revenue for the quarter was up 400.3% compared to the same quarter last year.
A number of institutional investors and hedge funds have recently modified their holdings of the stock. Creative Planning lifted its holdings in Pieris Pharmaceuticals by 18.2% during the 4th quarter. Creative Planning now owns 78,025 shares of the biotechnology company’s stock worth $589,000 after purchasing an additional 12,000 shares in the last quarter. Acadian Asset Management LLC raised its holdings in shares of Pieris Pharmaceuticals by 14.0% in the 4th quarter. Acadian Asset Management LLC now owns 116,154 shares of the biotechnology company’s stock valued at $877,000 after acquiring an additional 14,263 shares in the last quarter. New York State Common Retirement Fund raised its holdings in shares of Pieris Pharmaceuticals by 107.5% in the 3rd quarter. New York State Common Retirement Fund now owns 33,000 shares of the biotechnology company’s stock valued at $190,000 after acquiring an additional 17,100 shares in the last quarter. Wells Fargo & Company MN purchased a new stake in shares of Pieris Pharmaceuticals in the 3rd quarter valued at about $105,000. Finally, Bank of Montreal Can purchased a new stake in shares of Pieris Pharmaceuticals in the 4th quarter valued at about $144,000. 50.45% of the stock is currently owned by institutional investors and hedge funds.
In related news, major shareholder Orbimed Advisors Llc sold 147,635 shares of the stock in a transaction dated Monday, December 18th. The stock was sold at an average price of $5.70, for a total transaction of $841,519.50. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Corporate insiders own 4.05% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Pieris Pharmaceuticals Inc to Post FY2017 Earnings of ($0.44) Per Share, William Blair Forecasts (PIRS)” was reported by Ticker Report and is the property of of Ticker Report. If you are viewing this report on another site, it was illegally stolen and republished in violation of US and international copyright & trademark laws. The legal version of this report can be viewed at https://www.tickerreport.com/banking-finance/3148211/pieris-pharmaceuticals-inc-to-post-fy2017-earnings-of-0-44-per-share-william-blair-forecasts-pirs.html.
About Pieris Pharmaceuticals
Pieris Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.
Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.